Inhibition of RNA polymerase II-activating CDK9 and CDK12/13, but not of cell cycle relevant CDKs, induces apoptosis by downregulating the short-lived Bcl-2 proteins Mcl1 and Bfl1/A1
Authors:
- Sebastian WesselborgSebastian Wesselborg
- Karina KringsKKKarina Krings
- Judith HatzfeldJHJudith Hatzfeld
- Sandra WellerSWSandra Weller
- Nadine BorkowskiNBNadine Borkowski
- Tanya LlewellynTLTanya Llewellyn
- Laura SchmittLSLaura Schmitt
- Bo SchererBSBo Scherer
- Christoph PeterCPChristoph Peter
- Björn StorkBjörn Stork
- Stefanie GeyhSGStefanie Geyh
Preprint
- 19 December 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Cyclin-dependent kinases (CDKs) play a crucial role in cell cycle (such as CDK1 and CDK4/6) and transcription (such as CDK7, CDK9, and CDK12/13). While CDK inhibitors are clinically effective in cancer therapy, their mechanisms of apoptosis induction remain incompletely understood. Here, we demonstrate that inhibition of cell cycle CDKs (CDK1, CDK4/6) or transcriptional initiation (CDK7) did not induce cytotoxicity. Only inhibition of CDK9 (by AZD4573 and atuveciclib) and of CDK12/13 (by SR4835 and THZ531) – which target the transcriptional elongation of RNA polymerase II (RNAPII) – exerted a strong apoptotic potential. Since CDK9 and CDK12/13 target different elongation factors associated with RNAPII (such as SPT6 and NELF for CDK9; CDC73, and LEO1 for CDK12/13), they cannot substitute for each other. Consequently, the combination of AZD4573 with SR4835 resulted in significant, synergistic cytotoxicity. Inhibiting CDK9 or CDK12/13 induced the rapid downregulation of the short-lived, anti-apoptotic Bcl-2 proteins Mcl1 and A1/Bfl1 in Jurkat leukemia cells and SUDHL1 lymphoma cells, whereas the expression of Bcl-2 and Bcl-xL remained unaffected. Since Mcl1 and A1 antagonize the pro-apoptotic Bcl-2 proteins Bak and Bax, apoptosis induction by AZD4573 or SR4835 was blocked in Bak- and Bax/Bak-deficient Jurkat cells and strongly reduced in Bax-deficient cells. Because Bcl-2 only inhibits Bax, but not Bak, AZD4573 and SR4835 were able to induce apoptosis in Jurkat cells overexpressing Bcl-2. As tumor cells frequently upregulate Bcl-2, inhibitors of CDK9 and CDK12/13 represent promising anticancer drugs.Keywords
All Related Versions
This publication has 86 references indexed in Scilit:
- CDK7 inhibitors as anticancer drugsCancer and Metastasis Reviews, 2020
- CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung CancerCancer Cell, 2019
- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast CancerCancer Cell, 2019
- Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistanceCancer Letters, 2019
- Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerChemMedChem, 2017
- Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 InhibitorCancer Cell, 2014
- Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestrationBiochemical Pharmacology, 2012
- The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cellsJournal of Gastroenterology, 2009
- Mcl-1: a highly regulated cell death and survival controllerJournal of Biomedical Science, 2006
- A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometryJournal of Immunological Methods, 1991